Updated 14:15 GMT, 21 Nov 2026 SPX 6,910.39 -3.70% NDX 25,028.98 -5.61% VIX 35.89 +26.20% GOLD 3,515.40 -4.62% CL 83.98 +0.93% BTC 60,166.89 +2.33%
NAS100 25,029 −5.61% S&P 6,910 −3.70% GOLD $3,515 −4.62% BTC $60,167 +2.33% VIX 35.89 +26.20% latest tape · as of 14:15 UTC
The Screen · Healthcare · Biotechnology

Vera Therapeutics, Inc. logoVera Therapeutics, Inc.

VERA · Nasdaq · USD · Market cap $1.9B · 339 employees

Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development and commercialization of transformative treatments for patients with immunological diseases.

FAIL · Does not pass the screen
25.45 USD

Price as of 20 Nov 2026Daily close, not a live quote

Screened 2026-11-20 · the tape above runs as of 14:15 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed

Key facts today

  • Price25.45 USD at the 20 Nov 2026 close
  • Fair valueUnder review: our model's value is 2.93x the price, above our 2.00x limit.
  • Our regime readMarkup, as of 15 Nov 2026
  • Ethical screenDoes not pass
  • OptionsOpen interest leans heavily to calls (put/call 0.19)
  • Last reviewed20 Nov 2026 (1 day ago)
  • Release timesRelease and earnings times on your chart: Event Guard Mentor

A summary of the dated readings below, not a live quote and not advice.

PRICE · ONE YEAR

Our fair-value range: range not available (screen dated 2026-11-20).

Current read
Markup ?
Screened · screened 2026-11-20
  • Trend Markup
  • Insiders no filings inside 60 days, left as found
  • Positioning no disclosures inside 60 days, left as found
  • Options put/call open interest 0.19, read 2026-11-19
  • Ethical does not pass the values gate
Price25.45 USD
Fair valueUnder review
Ethical score70.0/100
Our investment reviews on this name
2026-11-05Read Markup31.97-20.4% to today Distribution gives way to Markup after a 6% slide in 5 weeks
2026-10-02Read Distribution34.00-25.1% to today ✓Markup gives way to Distribution first Distribution read since August
2026-09-16Read Markup33.67-24.4% to today Distribution gives way to Markup with results news in the headlines
2026-07-02Read Distribution34.26-25.7% to today ✓First review on file: Distribution

Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.

The full research record, in depth, below
The Label · The Season, Not the Day

This name holds its markup label.

Vera Therapeutics, Inc. holds its Markup at $25.45. The statistical read favours the sellers, held for 69 days.

As held on the ledger · 2026-11-20
PhaseMarkup
Quantitative stateThe statistical read favours the sellers, held for 69 days
Price at the screen$25.45
ValuationN/A trailing · -6.69 forward price to earnings
Values screenFAIL · score 70.0
Beta1.19
The Workings

Five Screens: VERA's Results

FAIL. Interest-bearing securities

TestFigureLimitStatus
Business activity Permissible Permissible core business Pass
Debt load 10.52% Below 33% Pass
Interest-bearing cash 48.98% Below 33% Fail
Receivables 48.73% Below 49% Pass

Definitions, sources and threshold rules: ticker values-screen methodology.

The Ethical Read

Why It Falls Short, in Plain English

Vera Therapeutics,'s business is fine, but its cash and interest-bearing securities are about 49% of its assets, well over the ~33% line, so it does not pass on the financial screens.

Read as at 20 Nov 2026. It updates when the underlying figures move, and past reads are kept below. How we screen.

Follow this verdict

Get an email when VERA's ethical verdict changes

Today VERA does not pass the screen. If new figures move it to a pass, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.

Free, no account needed. Every email has a link to stop.

What the Numbers Say It Is Worth

The Fair Value Range

Fair value under review. Our model's value is 2.93x the price, above our 2.00x limit. We show no fair value, margin of safety or value read built on it until the review clears.

Method.

The Street's Range
29.00Street low 75.00Street average 100.00Street high 25.45Price

Street: 14 covering, consensus Strong Buy. Average target +195%.

Chart
The Business, in Plain Words

Early stage drug developer lacks financial track record

A clinical stage biotech chasing new treatments for immune diseases can grab attention when analysts line up behind a high price target. Vera sits at 38.50 dollars against a median broker view of 82 dollars and our own fair value of 77 dollars. Yet the opportunity rating sits at none because the ethical screen returns insufficient data and key ratios are missing.

The business shows zero profit margin, negative 71 percent return on equity and a forward multiple of negative 10 times that reflects ongoing losses rather than earnings power. With no moat identified and still pre commercial, the story rests on one candidate drug whose success remains unproven in the market.

Risks centre on the total absence of reliable financial history plus the ethical gap that blocks any further review. Clinical outcomes can shift quickly and funding needs may dilute holders long before any revenue appears. Analysis, not advice.

The fundamentals · plain-English read
Forward P/E-6.7x
EPS, trailing-5.90
EPS, forward-3.92
Profit margin0.0%currently unprofitable
Return on equity-113.5%not currently earning a positive return on equity
FCF yield-12.91%
Debt to equity0.23minimal debt: a conservative balance sheet
Current ratio7.91comfortably covers its short-term bills
Beta1.19moves a little more than the market
Short interest, float0.19%
52-week range25.82 - 56.05
Market cap$1.9B
Employees339

VERA-specific watchpoints · The things to watch: it's a small-cap, so the share price can swing harder than the market; as a biotechnology name, trial and regulatory outcomes can move it sharply either way.

Metric definitions and interpretation rules: ticker-page methodology.

The Dated Journal · Newest First, Never Edited

Every Entry, As Written

2026-11-20 Markup $25.58 +0.0% Entry 20
2026-11-19 Markup $25.58 -16.1% Entry 19
2026-11-12 Markup $30.48 -4.7% Entry 18
2026-11-05 Markup · changed $31.97 +4.1% Entry 17

The framework has shifted from distribution to markup since the last review.

2026-11-04 Distribution $30.71 -0.9% Entry 16
2026-11-03 Distribution $30.98 +0.0% Entry 15
2026-11-02 Distribution $30.98 +0.0% Entry 14
2026-11-01 Distribution $30.98 +10.7% Entry 13
2026-10-31 Distribution $27.99 +0.0% Entry 12
2026-10-30 Distribution $27.99 +0.0% Entry 11

Earnings landed in this window. Ethical screening: FAIL.

Written on its date, before the outcome; never pruned.

Latest News · What the Market Is Reading on VERA

Headlines from third-party outlets, linked for reference: not our reporting, not advice.

Related Securities · Others in VERA's Space

Screened names in the same industry · explore each on its own page.

The Political Ledger · Congressional Disclosures
Disclosures naming VERA
DatePoliticianPartyTypeAmount
2026-09-25 Ro Khanna Democrat sell 1K–15K
2026-09-25 Ro Khanna Democrat sell 1K–15K
2026-09-11 Ro Khanna Democrat sell 1K–15K
2026-09-11 Ro Khanna Democrat sell 1K–15K
2026-09-11 Ro Khanna Democrat sell 1K–15K
What Holding Actually Paid · Price Plus Dividends
If $1,000 had been placed · historical, not a promise
PeriodPrice thenPrice returnDivs per share$1,000 becameTotal return
1 month $36.61 -13.6% · $864 -13.6%
2 months $45.04 -29.8% · $702 -29.8%
3 months $41.17 -23.2% · $768 -23.2%
6 months $46.02 -31.3% · $687 -31.3%
1 year $22.62 +39.8% · $1,398 +39.8%
2 years $38.98 -18.9% · $811 -18.9%
3 years $7.77 +307.0% · $4,070 +307.0%
5 years $14.61 +116.4% · $2,164 +116.4%

Historical returns from market close data. Past performance does not guarantee future results.

The Ledger's Promise

This entry now belongs to the ledger. Whatever VERA does next, these words stay.

Vera Therapeutics, Inc. · VERA · Markup · $25.45
Recorded 2026-11-20 · before the outcome · scored mechanically

Membership

Thirteen thousand names carry this page. One desk keeps them honest.

Membership opens the full screen archive, the composites built from it, and the daily coverage that prices what the screen approves.

Join the desk

Screening is research, not a fatwa and not financial advice. Figures are drawn from public accounts at the screen date shown. Always manage your risk.

Get our weekly market brief free.